Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Hepatocellular 4Stomach Neoplasms 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Breast Neoplasms 3Spinocerebellar Degenerations 2Recurrence 2Rectal Neoplasms 2Neoplasms 2Gastric / Gastroesophageal Junction Adenocarcinoma 2EBV-associated Tumors 2Carcinoma, Non-Small-Cell Lung 2Vascular Complications 1Triple Negative Breast Neoplasms 1Solid Tumors 1Solid Cancers 1Small Cell Lung Carcinoma 1Pathologic Complete Response 1Pancreatic Neoplasms 1Pancreatic Cancer Metastatic 1Oropharyngeal Neoplasms 1Nasopharyngeal Cancinoma (NPC) 1Mouth Neoplasms 1Melanoma 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1Head and Neck Neoplasms 1Gynecologic Cancers 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1

Interventions

somatostatin receptor 2 1lenvatinib 1ensartinib 1Nivolumab 1Lutetium 1Injections 1Immune Checkpoint Inhibitors 1Fluorodeoxyglucose F18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Solid Tumors × Immune Checkpoint Inhibitors × Clear all
NCT07417501 2026-02-18

Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification

Tongji Hospital

Phase 2 Not yet recruiting
60 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡